Previous 10 | Next 10 |
2024-03-26 16:42:37 ET Gainers: nCino ( NCNO ) +14% . Biomea Fusion ( BMEA ) +7% . Poseida Therapeutics ( PSTX ) +5% . Office Properties Income ( OPI ) +5% . Canopy Growth Corporation ( CGC ) +4% . Losers: Bow...
2024-03-26 02:58:06 ET More on Poseida Therapeutics Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement Poseida spikes after FDA orphan status for CAR-T therapy Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical e...
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer PR Newswire SAN DIEGO , March 25, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients...
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference PR Newswire SAN DIEGO , March 19, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatme...
2024-03-17 00:40:48 ET Summary Additional results from the phase 1 study, using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory multiple myeloma, are expected at AACR on April 8th of 2024; Other data 2nd half of 2024. The global multiple myeloma market size is ...
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma PR Newswire Data Describing Activity of P-BCMA-ALLO1 in BCMA-Experienced Patients to be Presented at Upcoming AACR Meeting SAN DIEGO , Mar...
2024-03-13 08:22:59 ET More on Poseida Therapeutics Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics Financial informa...
2024-03-11 12:49:34 ET Gainers: Kidpik Corp ( PIK ) +118% . TC BioPharm ( TCBP ) +94% . L.S. Starrett Co. ( SCX ) +59% . Kingsoft Cloud Holdings Ltd ( KC ) +33% . Energem Corp ( ENCP ) +31% . NextNav ( NN ) +28% . ...
2024-03-07 17:16:08 ET More on Poseida Therapeutics Poseida Therapeutics: Non-Self CAR T Looks To Be Safe And Potentially Impactful Seeking Alpha’s Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics Financial informa...
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 PR Newswire Lead asset P-BCMA-ALLO1 Phase 1 clinical trial data presented at ASH 2023 demonstrated 82% ORR and favorable emerging safety and reliability profile Initia...
News, Short Squeeze, Breakout and More Instantly...
Poseida Therapeutics Inc. Company Name:
PSTX Stock Symbol:
NASDAQ Market:
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024 PR Newswire Expanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeti...
Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual Meeting PR Newswire Early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic rang...
2024-05-01 14:28:11 ET A California-based %Biotech company is turning heads on Wednesday after it announced that it entered into a research collaboration and license agreement with Astellas Pharma’s Xyphos Biosciences subsidiary. Shares of %PoseidaTherapeutics (Nasdaq: $P...